Investments in pharmaceutical companies linked to President Donald Trump’s portfolio surged significantly following his return to the White House in 2025, according to a report released Friday by the Joint Economic Committee’s minority Democrats. The report highlights that Trump’s holdings in pharmaceutical stocks increased from a reported maximum value of $1.7 million in 2024 to as much as $56.2 million by the end of 2025. A substantial portion, approximately $39.1 million, was invested in firms that gained from a Republican-backed provision exempting certain medications from Medicare price negotiations.
The Republican tax and spending legislation enacted in July 2025 expanded exemptions to Medicare’s ability to negotiate drug prices, particularly for treatments targeting rare diseases or conditions. This provision, often referred to as the “orphan drug exclusion,” effectively delayed or excluded some expensive drugs from price negotiations, allowing companies to maintain higher prices. The report detailed stock acquisitions within Trump’s portfolio amounting to approximately $2.55 million in pharmaceutical companies poised to benefit from these exemptions, with notable purchases—including up to $950,000 on the day the Senate passed the bill and $1 million in AbbVie stock shortly after the law took effect.
The analysis underscored concerns that beneficiaries under Medicare could face substantially higher costs for critical medications, especially certain cancer treatments such as Keytruda by Merck and Opdivo by Bristol Myers Squibb. The report estimated these patients might incur roughly $5,000 more annually for these drugs than they would if Medicare were allowed to negotiate prices, noting that Trump held investments in both companies.
While Trump has positioned lowering prescription drug costs as a hallmark of his healthcare agenda and struck agreements with pharmaceutical firms promising affordability improvements, the complex dynamics of drug pricing persist. Polling has shown widespread public skepticism about whether Trump is leveraging his presidency for personal financial gain.
Senator Maggie Hassan of New Hampshire, who leads the Joint Economic Committee’s Democratic minority caucus, criticized the findings as “outrageous and yet typical,” asserting that the American public repeatedly bears the cost for the president’s personal enrichment. In response, Davis Ingle, a White House spokesperson, stated that Trump’s assets are managed by independent third parties, denying any involvement or conflicts of interest. "Neither President Trump nor any member of his family has any ability to direct, influence, or provide input regarding how the portfolio is invested or when investments are bought or sold," the statement said.
The report also highlighted differences in conflict of interest approaches among recent presidents. Unlike his predecessors who divested holdings or placed assets in blind trusts before taking office, Trump has retained control over his broader business interests through a trust managed by his sons, foregoing the conflict safeguards typically adopted by recent administrations.
The legislative changes follow earlier efforts by the Biden administration that granted Medicare the authority to negotiate prices for some high-cost drugs. However, Republicans’ 2025 tax and spending bill notably broadened exceptions that critics argue favor pharmaceutical companies by preserving their pricing power over lucrative medications while supporters claim the carve-outs are necessary to incentivize research into treatments for rare diseases.
Throughout the first eight months of 2026, Trump’s portfolio reportedly continued active trading in the pharmaceutical sector, increasing stock holdings by up to $3.5 million. The evolving financial landscape around drug pricing and presidential investments remains a subject of scrutiny amid ongoing debates over healthcare costs in the United States.